Table 3 Safety Analysis between PD-1 group and PD-L1 group
Adverse event | All patients (n = 154) | PD-1 group (n = 68) | PD-L1 group (n = 86) | p value | ||||
|---|---|---|---|---|---|---|---|---|
Any grade (%) | ≥ 3 grade (%) | Any grade (%) | ≥ 3 grade (%) | Any grade (%) | ≥ 3 grade (%) | Any grade (%) | ≥ 3 grade (%) | |
White blood cell decreased | 93 (60.4) | 28 (18.2) | 36 (52.9) | 11 (16.2) | 57 (66.3) | 17 (19.8) | 0.093 | 0.566 |
Anemia | 96 (62.3) | 13 (8.4) | 41 (60.3) | 8 (11.8) | 55 (64) | 5 (5.8) | 0.642 | 0.187 |
Platelet count decreased | 28 (18.2) | 13 (8.4) | 13 (19.1) | 6 (8.8) | 15 (17.4) | 7 (8.1) | 0.789 | 0.879 |
Liver damage | 56 (36.4) | 8 (5.2) | 21 (30.9) | 2 (2.9) | 35 (40.7) | 6 (7) | 0.209 | 0.450 |
Total bilirubin increased | 22 (14.3) | 0 (0) | 8 (11.8) | 0 (0) | 14 (16.3) | 0 (0) | 0.427 | - |
Direct bilirubin increased | 16 (10.4) | 2 (1.3) | 6 (8.8) | 0 (0) | 10 (11.6) | 2 (2.3) | 0.571 | 0.504 |
Renal injury | 15 (9.7) | 1 (0.6) | 6 (8.8) | 1 (1.5) | 9 (10.5) | 0 (0) | 0.733 | 0.442 |
Creatine kinase increased | 18 (11.7) | 2 (1.3) | 5 (7.4) | 1 (1.5) | 13 (15.1) | 1 (1.2) | 0.136 | 1.000 |
Hypopotassemia | 50 (32.5) | 8 (5.2) | 24 (35.3) | 6 (8.8) | 26 (30.2) | 2 (2.3) | 0.505 | 0.150 |
Amylase increased | 6 (3.9) | 0 (0) | 1 (1.5) | 0 (0) | 5 (5.8) | 0 (0) | 0.167 | - |
Lipase increased | 11 (7.1) | 4 (2.6) | 3 (4.4) | 1 (1.5) | 8 (9.3) | 3 (3.5) | 0.392 | 0.786 |
Pneumonia | 15 (9.7) | 10 (6.5) | 7 (10.3) | 3 (4.4) | 8 (9.3) | 7 (8.1) | 0.837 | 0.547 |
Peripheral neuritis | 2 (1.3) | 1 (0.6) | 2 (2.9) | 1 (1.5) | 0 (0) | 0 (0) | 0.193 | 0.442 |
Rash | 8 (5.2) | 0 (0) | 5 (7.4) | 0 (0) | 3 (3.5) | 0 (0) | 0.479 | - |
Gastrointestinal reaction | 50 (32.5) | 1 (0.6) | 21 (30.9) | 0 (0) | 29 (33.7) | 1 (1.2) | 0.709 | 1.000 |
Fatigue | 11 (7.1) | 1 (0.6) | 2 (2.9) | 0 (0) | 9 (10.5) | 1 (1.2) | 0.137 | 1.000 |
Pyrexia | 2 (1.3) | 0 (0) | 1 (1.5) | 0 (0) | 1 (1.2) | 0 (0) | 1.000 | - |
Alopecia | 17 (11) | 1 (0.6) | 4 (5.9) | 0 (0) | 13 (15.1) | 1 (1.2) | 0.069 | 1.000 |
Hypothyroidism | 17 (11) | 0 (0) | 7 (10.3) | 0 (0) | 10 (11.6) | 0 (0) | 0.997 | - |
Hyperthyroidism | 3 (2) | 0 (0) | 2 (1.3) | 0 (0) | 1 (1.2) | 0 (0) | 0.904 | - |